BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

(NASDAQ:BFRG),(NASDAQ:BFRGW), GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and […]

Correction: iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering

(NASDAQ:ISPC), WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) — This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.

Weatherford Awarded Managed Pressure Drilling Contract for Woodside Energy’s Trion Deepwater Development

(NASDAQ:WFRD), HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced it has been awarded a significant contract to deliver Managed Pressure Drilling (MPD) services for the Trion project, a deepwater oil production project in Mexico operated by Woodside Petroleo Operaciones de Mexico, S. de R.L. de

Interpublic Declares Common Stock Dividend

(NYSE:IPG), New York, NY, July 28, 2025 (GLOBE NEWSWIRE) — Interpublic Group (NYSE: IPG) today announced that the company's Board of Directors has declared a quarterly dividend on IPG common stock of $0.33 per share, payable on September 16, 2025, to holders of record at the close of business on September 2, 2025. # #

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

(Euronext Growth Paris:ALCLS),(NasdaqGM:CLLS), NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

(Paris:DBV),(NASDAQ:DBVT), AMF Regulated InformationChatillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and

Universal Safety Products, Inc. (formerly Universal Security Instruments, Inc.) Announces its Fourth-Quarter and Year-End Results

Universal Safety Products, Inc. (formerly Universal Security Instruments, Inc.) Announces its Fourth-Quarter and Year-End Results GlobeNewswire July 28, 2025 OWINGS MILLS, Md., July 28, 2025 (GLOBE NEWSWIRE) — Universal Safety Products, Inc. (formerly Universal Security Instruments, Inc.) (NYSE American LLC: UUU) today announced its financial results for the fourth quarter and its fiscal year ended March

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference GlobeNewswire July 28, 2025 GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics,

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 GlobeNewswire July 28, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial

Hark Capital provides $65 million facility to portfolio companies managed by WM Partners

Hark Capital provides $65 million facility to portfolio companies managed by WM Partners GlobeNewswire July 28, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Hark Capital, through its managed funds, has announced the closing of a $65 million financing arrangement with portfolio companies managed by WM Partners, a middle-market private equity sponsor focused on

Scroll to Top